Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Jessica Golimowski

Physician Assistant North Tonawanda, NY Physician Assistant

NPI 1134838279 CMS profile 11417317

273 Division St, North Tonawanda, NY 14120

Open in the dashboard

General payments

$6,848

265 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Golimowski of North Tonawanda, NY is reported in the CMS Open Payments database as having received $6,848 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,795 132
2024 General $2,418 87
2023 General $1,635 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Golimowski
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jessica Golimowski were reported at $2,795. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jessica Golimowski Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $1,635 $167 $52–$557 $160
2024 $2,418 $178 $55–$600 $164
2025 $2,795 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $1,508 31 payments
  2. Amgen Inc. $1,464 69 payments
  3. Novo Nordisk Inc $762 33 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $560 20 payments
  5. GlaxoSmithKline, LLC. $452 14 payments
  6. Lilly USA, LLC $343 11 payments
  7. Exact Sciences Corporation $339 12 payments
  8. Paratek Pharmaceuticals, Inc. $323 21 payments
  9. Phathom Pharmaceuticals, Inc. $272 4 payments
  10. Corcept Therapeutics $179 7 payments
  11. Other $645 43 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $6,803 264 payments
  2. Education $45 1 payment
Products named General payments · program years 2023–2025
  1. Otezla $1,071 61 payments
  2. AIRSUPRA $860 18 payments
  3. Repatha Cardiology $544 34 payments
  4. Ozempic $500 22 payments
  5. FARXIGA $402 10 payments
  6. RYBELSUS $380 21 payments
  7. REPATHA Cardiovascular $362 27 payments
  8. NUZYRA $323 21 payments
  9. JARDIANCE $304 17 payments
  10. VOQUEZNA $272 4 payments
  11. Other $2,921 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

3,809

Median for Physician Assistant: 241

Drug cost

$477,860

Median for Physician Assistant: $4,110

Branded share of claims

20.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 62 $86,387
Ozempic Semaglutide Brand 43 $62,440
Jardiance Empagliflozin Brand 25 $41,208
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 48 $39,052
Januvia Sitagliptin Phosphate Brand 24 $34,755
Repatha Sureclick Evolocumab Brand 35 $33,644
Trulicity Dulaglutide Brand 13 $29,359
Vascepa Icosapent Ethyl Brand 36 $22,021
Xarelto Rivaroxaban Brand 14 $18,233
Mounjaro Tirzepatide Brand 13 $17,110

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$7,465

Medicare's payments for the services billed

Medicare patients

46

Average age 75

Services billed

123

26 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 41%
Ischemic heart disease 41%
Chronic kidney disease 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $305
$305 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $138
  • Lilly USA, LLC $125
$263 25 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $251
$251 — —
Repatha
  • Amgen Inc. $239
$239 35 —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $165
$165 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record